Apotex Recalls Paroxetine Hydrochloride Tablets Due to Chemical Contamination
Apotex Inc. is recalling Paroxetine Hydrochloride Controlled-Release Tablets 25 mg because they were manufactured with active pharmaceutical ingredient batches contaminated with residual materials and solvents.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves chemical contamination (residual materials and solvents) in a prescription drug, which fits the 'High' severity criteria for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Apotex Inc. is recalling specific lots of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg, 30-count bottles. The product is a prescription-only medication manufactured by GlaxoSmithKline in RTP, NC, and manufactured for Apotex Corp. in Weston, FL. The recall involves NDC 60505-3674-3 and specific lot numbers with expiration dates ranging from January 2015 to August 2015.
The recall was initiated because the product was manufactured with active pharmaceutical ingredient (API) batches that were contaminated with residual materials and solvents. This chemical contamination poses a potential risk to patients taking the medication.
The affected products were distributed nationwide and in Puerto Rico. Patients and healthcare providers should check their medication bottles for the specific lot numbers and expiration dates listed in the recall notice. If the medication matches the recalled lots, patients should stop using it and contact their healthcare provider or pharmacist for guidance on alternative treatment options.
The recalled product
- Product
- PAROXETINE HYDROCHLORIDE (PAROXETINE HYDROCHLORIDE)
- Brand
- PAROXETINE HYDROCHLORIDE
- Manufacturer
- Apotex Inc.
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- Lot # 2A002
- Exp. 01/15 Lot # 2A003
- Exp. 01/15 Lot # 2C004
- Exp. 03/15 Lot # 2C005
- Exp. 03/15 Lot # 2E008
- Exp. 05/15 Lot # 2F009
- Exp. 06/15 Lot # 2F010
- Exp. 06/15 Lot # 2H011
- Exp. 08/15 Lot # 2H012
- Exp. 08/15 Lot # 2H013
- Exp. 0815
UPCs (3)
- 0360505367436
- 0360505367535
- 0360505367337
Distribution
Part of a larger recall action
This product is one of 9 recalled by Apotex Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 9 products in this recall →Related recalls
Same brand · PAROXETINE HYDROCHLORIDE
- SevereApotex Recalls Paroxetine Hydrochloride Tablets Due to Chemical Contamination
FDA (Drugs) · 2014-09-10
- SevereApotex Recalls Paroxetine Hydrochloride Tablets Due to Chemical Contamination
FDA (Drugs) · 2014-09-10
Same manufacturer · Apotex Inc.
See all →- SevereApotex Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-06-24
- SevereApotex Recalls Equate Ranitidine Tablets Due to Possible NDMA Contamination
FDA (Drugs) · 2019-11-20
- SevereApotex Recalls Walgreens Wal-Zan 150 Tablets Due to NDMA Contamination Risk
FDA (Drugs) · 2019-11-20
- SevereApotex Recalls Equate Ranitidine Tablets Due to NDMA Contamination
FDA (Drugs) · 2019-11-20
- SevereRite Aid Ranitidine Tablets Recalled for Potential NDMA Contamination
FDA (Drugs) · 2019-11-20
Same hazard · chemical contamination
See all →- SevereAmerican Regent Recalls Acetylcysteine Solution Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereGas-X Extra Strength softgels contaminated with propylene glycol machine coolant
FDA (Drugs) · 2026-06-17
- HighDragonfly Thai ginger powder may be contaminated with lead
FDA (Food) · 2026-06-17
- SevereNaproxen Oral Suspension Recalled for Lead and Lithium Contamination
FDA (Drugs) · 2026-05-13
- HighFarmHouse Fresh benzoyl peroxide night lotion recalled over benzene contamination
FDA (Drugs) · 2026-04-22